Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
RG Advertising
TeraRecon

Approval of Expansion of Cardioverter Defibrillator Trial to Include MRI Full-Body Scans

By Medimaging International staff writers
Posted on 03 Jun 2014
A new magnetic resonance imaging (MRI)-compatible, implantable cardioverter defibrillators (ICDs) provide physicians with the complete diagnostic capabilities of a dual-chamber ICD, including atrial sensing and sophisticated shock reduction algorithms with only one lead.

Biotronik (Berlin, Germany), a manufacturer of cardiovascular medical devices, reported that the US Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI trial. The approval will allow patients enrolled in phase C of the trial to receive full-body scans, and for the first time, include patients with DX ICDs in the study.

Biotronik, in 2011, received CE marking of approval and became the first company worldwide with an ICD approved for use in a MRI scanner. The ProMRI study is the next step in making this technology widely available in the United States. Biotronik introduced DX technology in 2013 in the United States, and it has been rapidly accepted by US electrophysiologists. Patients prefer implants with less hardware while physicians benefit from dual-chamber diagnostic data.

“With the DX system, I gain important diagnostic and therapeutic information. For my primary prevention patients with no dual chamber pacing indication, the implant procedures are straightforward, and it makes sense to use as little hardware as possible,” said Harpreet S. Grewal, MD, FACC, FHRS, from Richmond Cardiology Associates (Richmond, VA, USA). “The potential to provide this therapy and have it approved for use in full-body MRI conditions adds clinical value.”

Phase C of the ProMRI trial is the final phase in a series of MRI compatibility trials conducted by Biotronik in rapid succession. Phase A and phase B of the trial evaluated the safety of Biotronik Entovis pacemaker systems during MRI scans. Phase A resulted in FDA approval on May 6, 2014, of Entovis systems for MRI scans with an exclusion zone. Phase B expanded the trial to evaluate the safety of Entovis pacemaker systems for full-body scans, including cardiac and thoracic spinal scans. Phase B is nearing completion and data will soon be submitted to FDA.

“We are anxiously awaiting the day when this important diagnostic capability, up to now only available to pacemaker patients, can also benefit ICD patients,” said Kevin Mitchell, vice president, clinical studies at Biotronik, Inc. “Biotronik is committed to extending its ProMRI technology to as many patients as possible. We were the first company to offer ICD patients in the United States MRI access, and remain the only company that provides single-chamber pacemaker patients access to this diagnostic tool.”

Every year, about 200,000 patients in the United States are implanted with ICDs, and studies estimate that 50%–75% of them will develop a clinical need for an MRI scan during their lifetime. MRI scans frequently provide improved diagnostic capabilities for specific that cannot be adequately examined by X-ray, computed tomography (CT), or ultrasound. The strong forces applied during an MRI scan can have a negative effect on both device and patient, and are usually contraindicated for pacemaker and ICD patients.

With its ProMRI technology, Biotronik has developed a solution to enable all cardiac rhythm patients’ access to MRI scanning. ProMRI technology is already used widely in Europe, including recent CE approval for MR-Conditional full-body and 3.0 Tesla scans with the Ilesto/Iforia ICD system. The Biotronik -sponsored trial has been in US subject recruitment since March 2013.

Related Links:

Biotronik



Channels

Nuclear medicine

view channel

Construction of Australian Nuclear Medicine Production Plant Begins

The new facility is being built as part of the Australian Nuclear Science and Technology Organisation (ANSTO; NSW, Australia) Nuclear Medicine (ANM) project, and includes an investment of USD 168.8 by the Australian government. The ANM project also includes the construction of a Synroc plant for treatment of radioactive... Read more

General/Advanced Imaging

view channel
Image: Measuring the Magnetic Activity in the Brain of a Child, Using a MEG machine. (Photo courtesy of Children\'s Hospital of Philadelphia).

Study Suggests Language Delay Linked to Chromosome Deletion in Children with Neurological Disorders

A study found that children with neuro-developmental problems born with DNA duplications or deletions on part of chromosome 16, show measurable delays in their ability to process sound and language.... Read more

Imaging IT

view channel

European Governments Adopting Country-Specific Electronic Health Record Implementation Models

Frost & Sullivan (Mountain View, CA, USA) has released a new analysis of the Electronic Health Records (EHR) market in Europe. The study analyzes the hospital and ambulatory EHR market. According to the study, the market earned revenues of USD 2.74 billion in 2014, and is expected to reach USD 3.69 billion in 2020.... Read more

Industry News

view channel

Long-Term Contract for Telehealth Services Awarded by German Health Insurance Company

Almeda (Munich, Germany), a subsidiary of SHL Telemedicine (Tel Aviv, Israel), has won a public tender for an 8-year contract worth EUR 16–20 million offered by Barmer GEK (Wuppertal, Germany), a health insurance company, to provide telehealth services to clients insured at Barmer. Barmer GEK was already a long-term client... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.